Doris Herrera Pol steps down after eight years on IFFIm’s Board
Doris Herrera Pol steps down after eight years on IFFIm’s Board
20 December 2023
![Doris Herrera Pol Doris Herrera Pol](/sites/default/files/2023-12/Doris-IMG_3521.jpg)
Doris Herrera Pol
Doris Herrera Pol wraps up three terms and eight years on the IFFIm Board of Directors on 31 December.
Doris Herrera Pol wraps up three terms and eight years on the IFFIm Board of Directors on 31 December. Doris has been involved with IFFIm since its 2006 launch when she was Director of Funding at the World Bank and traveled around the world to present the new concept to investors, later working around the clock to price IFFIm’s very first US$ 1 billion vaccine bond. During her service, she has helped guide IFFIm, promoting funding at efficient levels and expanding the diversity of IFFIm’s markets. She has helped IFFIm actively promote Gavi’s mission and has been a champion for Gavi and IFFIm diversifying and expanding. We invited her to share some of her experiences as she prepares for life after IFFIm.
How has IFFIm changed since the day you took it to the market 17 years ago?
As I see it, IFFIm has a proven track record as one of the most versatile multilateral finance mechanisms ever developed.
IFFIm was conceived and designed to efficiently frontload long-term pledges from then mostly triple-A sovereign donors. It does this by tapping the capital markets in anticipation of the incoming payments from those pledges. IFFIm has enabled Gavi to accelerate vaccination and immunisation programmes, and to help reduce the cost and expand the availability of vaccines by signaling to the market that it could support long-term demand.
Through the years, IFFIm has fulfilled these objectives and many other different functions for Gavi, as it adapted to changing global public health challenges. Here are some examples of its versatility beyond engaging the original sovereign donors and the capital markets to accelerate funding for vaccination and immunisation programmes:
- IFFIm has been able to accommodate new donors and renew and increase its asset base consistently, with donors’ strong support. It also has continued to fund cost-effectively despite changes in its donors’ credit rating landscape and its own ratings. IFFIm has been able to add new instruments to its toolkit, such as its guarantee facility to back Gavi’s long-term vaccine procurement contracts.
- Along the way, IFFIm also supported the introduction of new vaccines, like pentavalent and HPV, as these have been introduced.
- IFFIm funding at times has been backloaded as Gavi needed to better manage its donor cashflows and generate financial efficiencies.
- Last but not least, IFFIm has stepped up to fulfill additional immunisation-related mandates. The first such mandate, in 2019, was to provide financial support—as a Gavi programme—to the Coalition for Epidemic Preparedness Innovation (CEPI). Then in 2021, several donors came together swiftly to support the equitable distribution of COVID-19 vaccines and used IFFIm to support the funding needs of the Gavi COVAX Advance Market Commitment (or AMC), a fund that developed and procured COVID-19 vaccines for lower-income countries during the pandemic.
Now, IFFIm is working on a contingent financing mechanism to be able to, as swiftly as possible, support future pandemic preparedness efforts.
In sum, it is obvious that the investment in IFFIm by sovereign donors has yielded a huge positive return in terms of impact and scope, and that over the last 17 years IFFIm has been able to meet both anticipated and unanticipated needs and challenges in a surprisingly versatile way.
What do you think is next for ESG markets and impact investments like IFFIm?
The ESG market has experienced remarkable growth over the last decade, and I expect that it will continue to further expand in decades to come as the spotlight grows on global environmental and social challenges. There will of course be hiccups along the way, especially if there is not sufficient progress to harmonise the ESG market regulations and protocols, taxonomies and definitions, reporting requirements and ratings criteria, and/or if the market were to be discredited by unchecked greenwashing.
For IFFIm and other social bond issuers, as well as for green and sustainability bond issuers, my advice is to stay transparent and true to your mission, to maintain an ESG market reputation that is as pristine as possible.
Is there anything else you want to talk about?
I have been on IFFIm’s Board for eight years, and prior to this at the World Bank Treasury I was affiliated with IFFIm since the World Bank was awarded IFFIm’s Treasury Manager mandate in late 2005. I want to recognise the excellent partnership that IFFIm has had with Gavi and the World Bank throughout this time.
I have nothing but praise for Gavi’s leading role in making tremendous strides in improving lives and reducing child mortality in poor countries. The Gavi board, the Gavi Chairs, and Gavi management and staff with whom I have had the pleasure to work through the years have all been incredibly motivated, dedicated and indefatigable.
At the same time, IFFIm wouldn’t have existed, and flourished as it has, without the tremendous backing of many World Bank colleagues for whom IFFIm’s mission resonates deeply.
![Doris Herrera-Pol and Ken Lay during the Raising Generation ImmUnity Conference, June 2023.](/sites/default/files/2023-07/gen-immunity-iffim-1.jpg)
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
Lifesaving immunisation: progress made possible by IFFIm
29 August 2024
Strengthening Gavi's replenishment with IFFIm
29 August 2024
IFFIm Board of Directors welcomes three new members
01 July 2024